These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Functions and dysfunctions of oligodendrocytes in neurodegenerative diseases. Han S; Gim Y; Jang EH; Hur EM Front Cell Neurosci; 2022; 16():1083159. PubMed ID: 36605616 [TBL] [Abstract][Full Text] [Related]
46. Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers. Zhang M; He P; Bian Z Front Mol Neurosci; 2021; 14():685143. PubMed ID: 34421536 [TBL] [Abstract][Full Text] [Related]
47. Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases. González LF; Bevilacqua LE; Naves R Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959337 [TBL] [Abstract][Full Text] [Related]
48. Deciphering the roles of caveolin in neurodegenerative diseases: The good, the bad and the importance of context. Yang W; Geng C; Yang Z; Xu B; Shi W; Yang Y; Tian Y Ageing Res Rev; 2020 Sep; 62():101116. PubMed ID: 32554058 [TBL] [Abstract][Full Text] [Related]
49. Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects. Faysal M; Dehbia Z; Zehravi M; Sweilam SH; Haque MA; Kumar KP; Chakole RD; Shelke SP; Sirikonda S; Nafady MH; Khan SL; Nainu F; Ahmad I; Emran TB Neurochem Res; 2024 Aug; 49(8):1926-1944. PubMed ID: 38822985 [TBL] [Abstract][Full Text] [Related]
50. The involvement of microRNAs in neurodegenerative diseases. Maciotta S; Meregalli M; Torrente Y Front Cell Neurosci; 2013 Dec; 7():265. PubMed ID: 24391543 [TBL] [Abstract][Full Text] [Related]
51. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases. Attia MS; Yahya A; Monaem NA; Sabry SA Saudi Pharm J; 2023 Mar; 31(3):417-432. PubMed ID: 37026045 [TBL] [Abstract][Full Text] [Related]
52. Dietary glycation compounds - implications for human health. Hellwig M; Diel P; Eisenbrand G; Grune T; Guth S; Henle T; Humpf HU; Joost HG; Marko D; Raupbach J; Roth A; Vieths S; Mally A Crit Rev Toxicol; 2024 Sep; 54(8):485-617. PubMed ID: 39150724 [TBL] [Abstract][Full Text] [Related]
53. Ion Channels in Neurological Disorders. Kumar P; Kumar D; Jha SK; Jha NK; Ambasta RK Adv Protein Chem Struct Biol; 2016; 103():97-136. PubMed ID: 26920688 [TBL] [Abstract][Full Text] [Related]
54. Association between Cerebrospinal Fluid Soluble Zhou W; Zhou Y; Li J J Clin Med; 2023 May; 12(10):. PubMed ID: 37240695 [TBL] [Abstract][Full Text] [Related]
55. Metals and neurodegenerative diseases. A systematic review. Cicero CE; Mostile G; Vasta R; Rapisarda V; Signorelli SS; Ferrante M; Zappia M; Nicoletti A Environ Res; 2017 Nov; 159():82-94. PubMed ID: 28777965 [TBL] [Abstract][Full Text] [Related]
56. Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine. Kadyan P; Singh L Pharmacol Rep; 2024 Aug; 76(4):665-678. PubMed ID: 38758470 [TBL] [Abstract][Full Text] [Related]